Market Overview

UPDATE: J.P. Morgan Initiates Coverage on AbbVie with Neutral Rating, $38 PT

Related ABBV
Fast Money Halftime Report Final Trade From November 24
Stocks Hitting 52-Week Highs
Making Money With Charles Payne: 10/20/14 (Fox Business)

In a report published Wednesday, J.P. Morgan & Co. initiated coverage on AbbVie (NYSE: ABBV) with a Neutral rating and $38.00 price target.

J.P. Morgan noted, “We are initiating coverage of ABBV shares with a Neutral rating and $38 YE'13 price target. We see AbbVie as essentially a Humira story until the company is able to further diversify its business. While Humira is a well-positioned franchise and we are above the Street with our estimates over the next several years, we do not see ABBV shares getting credit for these results given the longer-term competitive threats facing the product. Rather, we believe portfolio diversification will be a key driver of multiple expansion and outperformance for the stock, and this remains several years away, in our view.”

AbbVie closed on Monday at $34.16.

Latest Ratings for ABBV

DateFirmActionFromTo
Nov 2014Deutsche BankInitiates Coverage onOutperform
Nov 2014JefferiesMaintainsBuy
Nov 2014JP MorganMaintainsOverweight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Initiation Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Get Benzinga's Newsletters